VistaGen Therapeutics, Inc.

Symbol: VTGN




Market price today

  • -0.8514

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 50.18M

    MRK Cap

  • 0.00%

    DIV Yield

VistaGen Therapeutics, Inc. (VTGN) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Shawn K. Singh J.D.
Full-time employees:32
City:South San Francisco
Address:343 Allerton Avenue

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

General Outlook

In simple terms, VistaGen Therapeutics, Inc. has 9.362 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.985% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.258%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.258%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -3.089% return, is a testament to VistaGen Therapeutics, Inc.'s adeptness in optimizing resource deployment. VistaGen Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.684%. Furthermore, the proficiency of VistaGen Therapeutics, Inc. in capital utilization is underscored by a remarkable -4.233% return on capital employed.

Stock Prices

VistaGen Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $5.92, while its low point bottomed out at $5.1. This variance in figures offers investors a lucid insight into the roller-coaster ride that is VistaGen Therapeutics, Inc.'s stock market.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of VistaGen Therapeutics, Inc. (VTGN) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -0.851 in 2023.

What is the ticker symbol of VistaGen Therapeutics, Inc. stock?

The ticker symbol of VistaGen Therapeutics, Inc. stock is VTGN.

What is company IPO date?

IPO date of VistaGen Therapeutics, Inc. is 2011-06-21.

What is company current share price?

Current share price is 5.360 USD.

What is stock market cap today?

The market cap of stock today is 50182678.000.

What is PEG ratio in 2023?

The current 0.000 is 0.000 in 2023.

What is the number of employees in 2023?

In 2023 the company has 32.